RYVU Therapeutics S.A. — Proxy Solicitation & Information Statement 2026

Jun 3, 2026

Report Content Submission of Candidates for the Supervisory Board of the Company

The Management Board of Ryvu Therapeutics S.A. with its registeredoffice in Kraków, Poland (the "Company") hereby announces that, inconnection with the Ordinary General Meeting of the Company convened forJune 25, 2026, as announced by the Company in Current Report No.10/2026dated May 29, 2026, the agenda of which includes, among other matters,the adoption of resolutions regarding the appointment of members of theCompany's Supervisory Board, the Company has received from Mr. PawełPrzewięźlikowski, a shareholder holding more than 5% of the votingrights at the Company's Ordinary General Meeting, nominations of thefollowing persons as candidates for the Supervisory Board of the Companyfor the new term of office:

1. Mr. Piotr Romanowski - Chairman of the Company's Supervisory Board;

2. Mr. Tadeusz Wesołowski - Vice-Chairman of the Company's SupervisoryBoard;

3. Mr. Rafał Chwast - Member of the Company's Supervisory Board;

4. Mr. Scott Z. Fields - Member of the Company's Supervisory Board;

5. Mr. Peter Smith - Member of the Company's Supervisory Board.

All of the above-mentioned individuals currently serve as members of theCompany's Supervisory Board. Their professional biographies areavailable on the Company's website at: https://ryvu.com/about-us underthe "Supervisory Board" section. The nominated candidates have consentedto stand for election.

The shareholder's nomination letter is attached to this report.

Disclaimer: This English language translation has been prepared solelyfor the convenience of English speaking readers. Despite all the effortsdevoted to this translation, certain discrepancies, omissions orapproximations may exist. In case of any differences between the Polishand the English versions, the Polish version shall prevail. RyvuTherapeutics S.A., its representatives and employees decline allresponsibility in this regard.